Filing Details

Accession Number:
0000911916-16-000693
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-01 16:43:56
Reporting Period:
2016-12-01
Filing Date:
2016-12-01
Accepted Time:
2016-12-01 16:43:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348649 Colucid Pharmaceuticals Inc. CLCD Pharmaceutical Preparations (2834) 203419541
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1612396 D Matthew Dallas C/O Colucid Pharmaceuticals, Inc.
222 Third Street
Cambridge MA 02142
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-12-01 1,473 $35.17 41,601 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
  2. Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
  3. Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.